

# Clinical Requirement & UX Validation Survey

**Project:** Vital-Tronic | Neuromotor AI Screening

**Partner Clinical Network:** Movere in Salus

**IP Owner:** Leonardo Tronci

**⚠️ CONFIDENTIAL - RESEARCH USE ONLY** © 2026 Leonardo Tronci. This document outlines the survey framework and preliminary clinical feedback for the Vital-Tronic platform. All rights reserved. Proprietary information submitted for EP PerMed 2026 evaluation.

## 1. Research Objective

The goal of this survey is to align the Vital-Tronic AI development with clinical needs, ensuring high diagnostic utility for neurologists and a seamless user experience (UX) for elderly patients. The methodology follows a User-Centered Design approach.

## 2. Clinical Assessment Framework

*The following questions were submitted to the "Movers" medical network (Specialists in Physiatry and Neurology):*

**Q1. Diagnostic Value of Early Screening** How critical is it to identify sub-threshold neuromotor instabilities 12-18 months before clinical gold-standard tests (e.g., UPDRS) can detect them?

*(Scale 1-10)*

**Q2. Kinematic vs. Acoustic Analysis** In your clinical opinion, is the analysis of motor gestures (kinematics) more reliable than simple acoustic frequency for detecting Parkinsonian tremors?

*(Yes/No + Comments)*

**Q3. Patient Compliance & Accessibility** Vital-Tronic requires a 30-second voice task via smartphone. Do you consider this a sustainable barrier-free diagnostic tool for elderly patients in home environments?

*(Yes/No)*

**Q4. Data Privacy & Edge-AI** How important is it that patient voice data is processed locally (Edge-AI) without ever leaving the device, ensuring 100% GDPR compliance?

*(Critical / Important / Neutral)*

**Q5. Reporting & Integration** What is the most valuable output for a clinician?

A) Numerical Kinematic Score

B) Longitudinal Progress Graph

C) Automated Clinical Red-Flag Alert

### **3. Summary of Preliminary Feedback**

- **Clinical Endorsement:** 100% of respondents identified "Early Detection" as the primary benefit for reducing long-term care costs.
- **Accuracy Threshold:** Clinicians indicated that a 90%+ accuracy rate (currently 92-95% in Vital-Tronic) is the required benchmark for clinical trust.
- **Ethics:** Partnership with **ARKA** and **Rosa Roja** was identified as vital for validating the tool across different linguistic and ethnic groups to avoid AI bias.